Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia-TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial

Open access

Abstract

Background For children with sickle cell anaemia and high transcranial doppler (TCD) flow velocities, regular blood transfusions can effectively prevent primary stroke, but must be continued indefinitely. The efficacy of hydroxycarbamide (hydroxyurea) in this setting is unknown; we performed the TWiTCH trial to compare hydroxyurea with standard transfusions.Methods TWiTCH was a multicentre, phase 3, randomised, open-label, non-inferiority trial done at 26 paediatric hospitals and health centres in the USA and Canada. We enrolled children with sickle cell anaemia who were aged 4-16 years and had abnormal TCD flow velocities (≥ 200 cm/s) but no severe vasculopathy. After screening, eligible participants were randomly assigned 1:1 to continue standard transfusions (standard group) or hydroxycarbamide (alternative group). Randomisation was done at a central site, stratified by site with a block size of four, and an adaptive randomisation scheme was used to balance the covariates of baseline age and TCD velocity. The study was open-label, but TCD examinations were read centrally by observers masked to treatment assignment and previous TCD results. Participants assigned to standard treatment continued to receive monthly transfusions to maintain 30% sickle haemoglobin or lower, while those assigned to the alternative treatment started oral hydroxycarbamide at 20 mg/kg per day, which was escalated to each participant's maximum tolerated dose. The treatment period lasted 24 months from randomisation. The primary study endpoint was the 24 month TCD velocity calculated from a general linear mixed model, with the non-inferiority margin set at 15 cm/s. The primary analysis was done in the intention-to-treat population and safety was assessed in all patients who received at least one dose of assigned treatment. This study is registered with ClinicalTrials.gov, number NCT01425307.Findings Between Sept 20, 2011, and April 17, 2013, 159 patients consented and enrolled in TWiTCH. 121 participants passed screening and were then randomly assigned to treatment (61 to transfusions and 60 to hydroxycarbamide). At the first scheduled interim analysis, non-inferiority was shown and the sponsor terminated the study. Final model-based TCD velocities were 143 cm/s (95% CI 140-146) in children who received standard transfusions and 138 cm/s (135-142) in those who received hydroxycarbamide, with a difference of 4·54 (0·10-8·98). Non-inferiority (p=8·82 × 10(-16)) and post-hoc superiority (p=0·023) were met. Of 29 new neurological events adjudicated centrally by masked reviewers, no strokes were identified, but three transient ischaemic attacks occurred in each group. Magnetic resonance brain imaging and angiography (MRI and MRA) at exit showed no new cerebral infarcts in either treatment group, but worsened vasculopathy in one participant who received standard transfusions. 23 severe adverse events in nine (15%) patients were reported for hydroxycarbamide and ten serious adverse events in six (10%) patients were reported for standard transfusions. The most common serious adverse event in both groups was vaso-occlusive pain (11 events in five [8%] patients with hydroxycarbamide and three events in one [2%] patient for transfusions).Interpretation For high-risk children with sickle cell anaemia and abnormal TCD velocities who have received at least 1 year of transfusions, and have no MRA-defined severe vasculopathy, hydroxycarbamide treatment can substitute for chronic transfusions to maintain TCD velocities and help to prevent primary stroke.Funding National Heart, Lung, and Blood Institute, National Institutes of Health.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(15)01041-7

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 TWiTCH CONSORT flow diagram showing the enrollment, randomisation, and follow-up of the TWiTCH study participants.
Figure 1 TWiTCH CONSORT flow diagram showing the enrollment, randomisation, and follow-up of the TWiTCH study participants.CC BY-NC-ND · PubMed Central
Figure 2 Laboratory parameters based on intention-to-treat population: Panel A = hemoglobin concentration; Panel B = mean corpuscular volume; Panel C = %HbS; Panel D = %HbF; Panel E = white blood cell (WBC) count; Panel F = absolute neutrophil count (ANC); Panel G = absolute reticulocyte count (ARC); Panel H = serum ferritin. Complete blood counts and reticulocytes were measured locally, while hemoglobin electrophoresis and ferritin were analysed centrally. Data are illustrated as mean ± 1 standard deviation. The Standard Treatment Arm is portrayed in dashes while the Alternative Treatment Arm is shown by the solid line. All parameters are significantly different at exit (p<0.0001) between treatment groups except Panel A, with p=0.800.
Figure 2 Laboratory parameters based on intention-to-treat population: Panel A = hemoglobin concentration; Panel B = mean corpuscular volume; Panel C = %HbS; Panel D = %HbF; Panel E = white blood cell (WBC) count; Panel F = absolute neutrophil count (ANC); Panel G = absolute reticulocyte count (ARC); Panel H = serum ferritin. Complete blood counts and reticulocytes were measured locally, while hemoglobin electrophoresis and ferritin were analysed centrally. Data are illustrated as mean ± 1 standard deviation. The Standard Treatment Arm is portrayed in dashes while the Alternative Treatment Arm is shown by the solid line. All parameters are significantly different at exit (p<0.0001) between treatment groups except Panel A, with p=0.800.CC BY-NC-ND · PubMed Central
Figure 3 Primary study endpoint analysis of TCD velocities. The Standard (Transfusion) Arm data are portrayed as dashes while the Alternative (Hydroxyurea) Arm data are shown as a solid line. Panel A illustrates the TCD data using the mixed model statistical analysis, with baseline equivalence but divergence over time with lower velocities in the Alternative Arm. The curves are significantly different using the per-protocol non-inferiority comparison (p=8.82 × 10−16) and also by post-hoc analysis for superiority (p=0.023). Panel B illustrates the actual TCD velocity data in each arm as mean ± 1 standard deviation, including the number of participants evaluated at each 12-week time point. Panel C illustrates baseline (enrolment) and final (exit) maximum time-averaged mean TCD velocities for each participant. The lines at 170 and 200 cm/sec denote the normal and abnormal TCD boundaries, respectively. Open circles = Alternative Arm, Closed circles = Standard Arm.
Figure 3 Primary study endpoint analysis of TCD velocities. The Standard (Transfusion) Arm data are portrayed as dashes while the Alternative (Hydroxyurea) Arm data are shown as a solid line. Panel A illustrates the TCD data using the mixed model statistical analysis, with baseline equivalence but divergence over time with lower velocities in the Alternative Arm. The curves are significantly different using the per-protocol non-inferiority comparison (p=8.82 × 10−16) and also by post-hoc analysis for superiority (p=0.023). Panel B illustrates the actual TCD velocity data in each arm as mean ± 1 standard deviation, including the number of participants evaluated at each 12-week time point. Panel C illustrates baseline (enrolment) and final (exit) maximum time-averaged mean TCD velocities for each participant. The lines at 170 and 200 cm/sec denote the normal and abnormal TCD boundaries, respectively. Open circles = Alternative Arm, Closed circles = Standard Arm.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 32 references

Cited by

See all 554

Metadata

Authors
Ware, R. E., Davis, B. R., Schultz, W. H., Brown, R. C., Aygun, B., Sarnaik, S., Odame, I., Fuh, B., George, A., Owen, W., Luchtman-Jones, L., Rogers, Z. R., Hilliard, L., Gauger, C., Piccone, C., Lee, M. T., Kwiatkowski, J. L., Jackson, S., Miller, S. T., Roberts, C., Heeney, M. M., Kalfa, T. A., Nelson, S., Imran, H., Nottage, K., Alvarez, O., Rhodes, M., Thompson, A. A., Rothman, J. A., Helton, K. J., Roberts, D., Coleman, J., Bonner, M. J., Kutlar, A., Patel, N., Wood, J., Piller, L., Wei, P., Luden, J., Mortier, N. A., Stuber, S. E., Luban, N. L. C., Cohen, A. R., Pressel, S., & Adams, R. J.
Affiliations
  • Cincinnati Children's Hospital Medical Center (US)
  • Wayne State University (US)
  • Hospital for Sick Children (CA)
  • East Carolina University (US)
  • Baylor College of Medicine (US)
  • Children's Hospital of The King's Daughters (US)
  • The University of Texas Southwestern Medical Center (US)
  • University of Alabama at Birmingham (US)
  • Nemours Children's Clinic (US)
  • Case Western Reserve University (US)
  • Columbia University (US)
  • Children's Hospital of Philadelphia (US)
  • Medical University of South Carolina (US)
  • State University of New York (US)
  • University of South Carolina (US)
  • Boston Children's Hospital (US)
  • Children's Minnesota (US)
  • University of South Alabama (US)
  • St. Jude Children's Research Hospital (US)
  • University of Miami (US)
  • University of Mississippi (US)
  • Lurie Children's Hospital (US)
  • Duke Medical Center (US)
  • Augusta University (US)
  • Children's Hospital Los Angeles (US)
  • Children's National (US)
Corresponding author
Ware, Russell E
Venue
The Lancet
Publisher
Elsevier BV
Published
2016-02
Volume
387
Issue
10019
Pages
661-670
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W2189616037
Cited by
515
References
32
Citations by year
2026: 34 · 2025: 31 · 2024: 54 · 2023: 32 · 2022: 48 · 2021: 50 · 2020: 58 · 2019: 54 · 2018: 42 · 2017: 63 · 2016: 41
FWCI
27.80
Type
journal article
Language
en
Open access
Licence
  • cc-by-nc-nd
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)
Locations
  • The Lancet (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion, cc-by-nc-nd)
  • DukeSpace (Duke University) (submittedVersion, cc-by-nc-nd)
Funders
National Heart, Lung, and Blood Institute through grants (R01 HL-095647, R01 HL-095511)
Topics
  • Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
  • Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Neonatal Health and Biochemistry
  • Health Sciences › Medicine › Hematology › Blood transfusion and management
Keywords
sickle cell disease, hydroxyurea, chronic transfusion, stroke prevention, children, non-inferiority, hemoglobin S, vasculopathy, adverse events
MeSH terms
Adolescent, Anemia, Sickle Cell, Antisickling Agents, Blood Flow Velocity, Blood Transfusion, Cerebrovascular Circulation, Child, Child, Preschool, Combined Modality Therapy, Female, Humans, Hydroxyurea, Male, Treatment Outcome, Ultrasonography, Doppler, Transcranial, Stroke, Drug Substitution

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia-TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial. https://app.cochat.ai/papers/10.1016/s0140-6736(15)01041-7
The paper
Ware, R. E., Davis, B. R., Schultz, W. H., Brown, R. C., Aygun, B., Sarnaik, S., Odame, I., Fuh, B., George, A., Owen, W., Luchtman-Jones, L., Rogers, Z. R., Hilliard, L., Gauger, C., Piccone, C., Lee, M. T., Kwiatkowski, J. L., Jackson, S., Miller, S. T., . . . Adams, R. J. (2016). Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia-TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial. The Lancet. https://doi.org/10.1016/s0140-6736(15)01041-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.